Amgen To Present At The 2021 Jefferies Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Amgen (AMGN) PT Raised to $272 at Oppenheimer
June 1, 2021 3:29 PM EDTOppenheimer analyst Jay Olson raised the price target on Amgen (NASDAQ: AMGN) to $272.00 (from $270.00) while maintaining an Outperform rating.
The analyst commented, "AMGN announced FDA approval of Lumakras ~2.5 months ahead of the 8/16 PDUFA. The approval marks the first KRAS G12C... More
